ViaDerma(OTC) VDRM

Current Price$0.00

Market Cap$493.50K

Since IPO (2009)-100%

5 Year-98%

1 Year-20%

1 Month+0%

ViaDerma last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-20

ViaDerma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-13
1 month	+0%	USD 0.00	2026-06-18
3 month	+0%	USD 0.00	2026-04-21
Year to date	+100%	USD 0.00	2025-12-31
1 year	-20%	USD 0.00	2025-07-18
3 year	-96.26%	USD 0.01	2023-07-21
5 year	-98.26%	USD 0.02	2021-07-21
Since inception	-100%	USD 225.00	2009-08-06

ViaDerma Financials at a Glance

Market Cap

$493.50K

Revenue (TTM)

$600.88K

Net Income (TTM)

-$227.34K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.52 (Low)

Dividend

$0.00

Beta (Volatility)

-0.52 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Oct 1, 2025

Dividend

$0.00

Beta (Volatility)

-0.52 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Oct 1, 2025

VDRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ViaDerma

ViaDerma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products. The company is dedicated to addressing various therapeutic areas through its proprietary technology and product offerings.

Products and Services

Vitastem, a topical antibiotic effective for treating various skin ailments
Advanced topical antibiotics and antifungal treatments in development
Expanding pipeline including medical cannabis applications and anti-aging formulations

Growth Outlook

Ongoing development in multiple therapeutic areas enhances market potential
Recent quarterly revenue growth indicates increasing product demand
Focus on licensing proprietary technology to expand market reach

Financial Highlights

Q3 2024 revenue of $150,189 shows consistent performance
Gross profit margin remains high at approximately 99.97%
Cash and cash equivalents increased to $1,491,343 in Q3 2024

ViaDerma, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry. The company has established a strong foundation with its flagship product, Vitastem, which addresses a wide range of skin conditions. The ongoing development of additional products and technologies positions ViaDerma for future growth. Recent financial performance indicates a stable revenue stream, with a notable gross profit margin that reflects the efficiency of its operations. The increase in cash reserves further supports the company's ability to invest in research and development, enhancing its product pipeline and market presence. Overall, ViaDerma represents a compelling opportunity within the pharmaceutical landscape, driven by innovation and a commitment to addressing unmet medical needs.

AI Generated • Jun 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Chris Ayo Otiko, PhD

Website

www.viaderma.com

Headquarters

Las Vegas, NV 90292, US

VDRM Financials

Key Financial Metrics (TTM)

Gross Margin

99.97%

Operating Margin

30.85%

Net Income Margin

0.68%

Return on Equity

-0.48%

Return on Capital

41.53%

Return on Assets

0.32%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$493.50K

Shares Outstanding

1.23B

Volume

Avg. Volume

92.20K

Financials (TTM)

Gross Profit

$600.68K

Operating Income

-$145.83K

EBITDA

-$145.64K

Operating Cash Flow

-$506.84K

Capital Expenditure

$0.00

Free Cash Flow

-$506.84K

Cash & ST Invst.

$1.49M

Total Debt

$1.86M

ViaDerma Performance Analysis

ViaDerma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 514,007	N/A
2022	2022-12-31	USD 540,648	5.2%
2023	2023-12-31	USD 600,498	11.1%
2024	2024-12-31	USD 450,499	-25.0%

ViaDerma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	-0.1%
Q1	2024-03-31	0.3%
Q2	2024-06-30	-0.2%
Q3	2024-09-30	0.0%

ViaDerma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.00	N/A
2022	2022-12-31	USD 0.00	N/A
2023	2023-12-31	USD 0.00	N/A
2024	2024-12-31	USD -0.00	N/A

ViaDerma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	-100.0%
Q1	2024-03-31	N/A
Q2	2024-06-30	-100.0%
Q3	2024-09-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2024YOY CHG

Revenue

$150.19K

-0.0%

Gross Profit

$150.14K

-0.0%

Gross Margin

99.97%

N/A

Market Cap

$493.50K

N/A

Market Cap/Employee

$6.58K

N/A

Employees

N/A

Net Income

-$321.55K

-906.1%

EBITDA

-$294.40K

-606.4%

Quarterly Fundamentals

Name

Q3 2024YOY CHG

Total Cash

$1.49M

+15005.3%

Total Debt

$1.86M

+476.9%

Accounts Receivable

$4.00K

-99.6%

Inventory

$2.25M

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.86M

+476.9%

Return on Assets

0.32%

N/A

Return on Invested Capital

1.50%

N/A

Free Cash Flow

-$874.84K

-2916033.3%

Operating Cash Flow

-$874.84K

-2916040.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AOXGAoxing Pharmaceutical Company, Inc.

AOXGAoxing Pharmaceutical Company, Inc.$0.00+0.00%

SFLMSFLMaven Corp.

SFLMSFLMaven Corp.$0.00+0.00%

GSACGelStat Corporation

GSACGelStat Corporation$0.00+0.00%

GPFTGrapefruit USA, Inc.

GPFTGrapefruit USA, Inc.$0.00+0.00%

LRSVLink Reservations Inc.

LRSVLink Reservations Inc.$0.00+0.00%

RLBDReal Brands, Inc.

RLBDReal Brands, Inc.$0.00+0.00%

PZOOPazoo, Inc.

PZOOPazoo, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

TAT&T

TAT&T$24.13+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

STAKStak

STAKStak$9.27+6.02%

Questions About VDRM

What is the current price of ViaDerma?

ViaDerma is trading at $0.00 per share.

What is the 52-week range for ViaDerma?

Over the past 52 weeks, ViaDerma has traded between $0.00 and $0.01.

How much debt does ViaDerma have?

As of the most recent reporting period, ViaDerma reported total debt of $5.91M.

How much cash does ViaDerma have on hand?

ViaDerma reported $11.86K in cash and cash equivalents in its most recent financial results.

What is ViaDerma’s dividend yield?

ViaDerma does not currently have a dividend yield.

ViaDerma(OTC) VDRM

ViaDerma Financials at a Glance

VDRM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ViaDerma

VDRM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ViaDerma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VDRM

What is the current price of ViaDerma?

What is the 52-week range for ViaDerma?

How much debt does ViaDerma have?

How much cash does ViaDerma have on hand?

What is ViaDerma’s dividend yield?

Premium Investing Services